{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T20:08:05Z","timestamp":1772309285619,"version":"3.50.1"},"publisher-location":"Singapore","reference-count":63,"publisher":"Springer Singapore","isbn-type":[{"value":"9789813292703","type":"print"},{"value":"9789813292710","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-981-32-9271-0_11","type":"book-chapter","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T14:02:56Z","timestamp":1575036176000},"page":"201-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Optimized Treatment Strategy for Depressive Disorder"],"prefix":"10.1007","author":[{"given":"Peijun","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,30]]},"reference":[{"key":"11_CR1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/archpsyc.1996.01830090090013","volume":"53","author":"R Aronson","year":"1996","unstructured":"Aronson R, Offman HJ, Joffe RT, Naylor CD (1996) Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 53:842\u2013848","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"11_CR03","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4088\/JCP.v63n0813","volume":"63","author":"James G. Barbee","year":"2002","unstructured":"Barbee JG, Jamhour NJ (2002) Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 63:737\u2013741","journal-title":"The Journal of Clinical Psychiatry"},{"key":"11_CR2","unstructured":"Bauer M, Dell\u2019osso L, Kasper S, Pitchot W, Dencker Vansvik E, K\u00f6hler J, J\u00f8rgensen L, Montgomery SA (2013) J Affect Disord 151(1):209\u2013219. Epub 27 Jun 2013"},{"issue":"4","key":"11_CR01","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40263-014-0152-8","volume":"28","author":"Michael Bauer","year":"2014","unstructured":"Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M (2014) Role of lithium augmentation in the management of major depressive disorder. CNS Drugs 28(4):331\u2013342, Apr 2014","journal-title":"CNS Drugs"},{"issue":"48","key":"11_CR08","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18480","volume":"18","author":"Emma Bedson","year":"2014","unstructured":"Bedson E, Bell D, Carr D, Carter B, Hughes D, Jorgensen A, Lewis H, Lloyd K, McCaddon A, Moat S, Pink J (2014) Folate augmentation of Treatment\u2013Evaluation for Depression (FolATED): randomised trial and economic evaluation. Health Technol Assess 18:1\u2013159","journal-title":"Health Technology Assessment"},{"key":"11_CR3","first-page":"137","volume":"171C","author":"D Bennabi","year":"2014","unstructured":"Bennabi D, Aouizerate B, El-Hage W, Doumy O, Moliere F, Courtet P et al (2014) Risk factors for treatment resistance in unipolar depression: a systematic review. J Affect Disord 171C:137\u2013141","journal-title":"J Affect Disord"},{"issue":"4","key":"11_CR4","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1007\/s11033-014-3097-6","volume":"41","author":"D Berent","year":"2014","unstructured":"Berent D, Zboralski K, Orzechowska A, Ga\u0142ecki P (2014) Thyroid hormones association with depression severity and clinical outcome in patients with major depressive disorder. Mol Biol Rep 41(4):2419\u20132425","journal-title":"Mol Biol Rep"},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euroneuro.2009.01.015","volume":"19","author":"P Blier","year":"2009","unstructured":"Blier P, Gobbi G, Turcotte JE, de Montigny C, Boucher N, H\u00e9bert C, Debonnel G (2009) Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 19:457\u2013465","journal-title":"Eur Neuropsychopharmacol"},{"key":"11_CR6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1176\/appi.ajp.2009.09020186","volume":"167","author":"P Blier","year":"2010","unstructured":"Blier P, Ward HE, Tremblay P, Laberge L, H\u00e9bert C, Bergeron R (2010) Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 167:281\u2013288","journal-title":"Am J Psychiatry"},{"issue":"11","key":"11_CR7","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1038\/npp.2014.101","volume":"39","author":"E Brunner","year":"2014","unstructured":"Brunner E, Tohen M, Osuntokun O, Landry J, Thase ME (2014) Efficacy and safety of olanzapine\/fluoxetine combination vs. fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology 39(11):2549\u20132559","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"11_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4088\/JCP.16r10749","volume":"79","author":"Tom Bschor","year":"2018","unstructured":"Bschor T, Kern H, Henssler J, Baethge C (2018) Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. J Clin Psychiatry 79(1):16r10749","journal-title":"The Journal of Clinical Psychiatry"},{"key":"11_CR9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0006-3223(01)01262-8","volume":"51","author":"LL Carpenter","year":"2002","unstructured":"Carpenter LL, Yasmin S, Price LH (2002) A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51:183\u2013188","journal-title":"Biol Psychiatry"},{"issue":"2","key":"11_CR10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/JCP.0000000000000663","volume":"37","author":"Eun-Jin Cheon","year":"2017","unstructured":"Cheon EJ, Lee KH, Park YW, Lee JH, Koo BH, Lee SJ, Sung HM (2017) Comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors: a randomized, prospective, open-label study. J Clin Psychopharmacol 37(2):193","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"11_CR11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3810\/pgm.2010.07.2174","volume":"122","author":"L Citrome","year":"2010","unstructured":"Citrome L (2010) Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 122:39\u201348","journal-title":"Postgrad Med"},{"key":"11_CR12","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/ijcp.12714","volume":"69","author":"L Citrome","year":"2015","unstructured":"Citrome L (2015) Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Int J Clin Pract 69:978\u2013997","journal-title":"Int J Clin Pract"},{"issue":"15","key":"11_CR13","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1017\/S003329171700068X","volume":"47","author":"PJ Cowen","year":"2017","unstructured":"Cowen PJ (2017) Backing into the future: pharmacological approaches to the management of resistant depression. Psychol Med 47(15):2569\u20132577","journal-title":"Psychol Med"},{"key":"11_CR14","doi-asserted-by":"crossref","first-page":"935","DOI":"10.4088\/JCP.v68n0617","volume":"68","author":"NA Crossley","year":"2007","unstructured":"Crossley NA, Bauer M (2007) Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 68:935\u2013940","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"11_CR15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ijnp\/pyy052","volume":"22","author":"K Demyttenaere","year":"2019","unstructured":"Demyttenaere K, Van Duppen Z (2019) The impact of (the concept of) treatment-resistant depression: an opinion review. Int J Neuropsychopharmacol 22(2):85\u201392","journal-title":"Int J Neuropsychopharmacol"},{"issue":"7","key":"11_CR16","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1176\/ajp.2006.163.7.1161","volume":"163","author":"M Fava","year":"2006","unstructured":"Fava M, Rush AJ, Wisniewski SR et al (2006) A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 163(7):1161\u20131172","journal-title":"Am J Psychiatry"},{"issue":"8","key":"11_CR17","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.euroneuro.2014.04.004","volume":"24","author":"Michele Fornaro","year":"2014","unstructured":"Fornaro M, Martino M, Mattei C, et al (2014) Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 24(8):1269","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"11_CR18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/JCP.0b013e31823f705d","volume":"32","author":"BN Gaynes","year":"2012","unstructured":"Gaynes BN, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Miller WC, St\u00fcrmer T (2012) Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J Clin Psychopharmacol 32(1):114\u2013119","journal-title":"J Clin Psychopharmacol"},{"key":"11_CR19","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3389\/fnins.2018.00933","volume":"12","author":"W Ge","year":"2018","unstructured":"Ge W, Jakobsson E (2018) Systems biology understanding of the effects of lithium on affective and neurodegenerative disorders. Front Neurosci 12:933","journal-title":"Front Neurosci"},{"issue":"11","key":"11_CR09","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.4088\/JCP.13r08560","volume":"74","author":"Alexander J. Goss","year":"2013","unstructured":"Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH (2013) Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 74:1101\u20131107","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"Suppl 16","key":"11_CR20","first-page":"26","volume":"62","author":"JF Greden","year":"2001","unstructured":"Greden JF (2001) The burden of disease for treatment-resistant depression. J Clin Psychiatry 62(Suppl 16):26\u201331","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"11_CR21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1742-7843.2011.00788.x","volume":"110","author":"Gaurav Gulrez","year":"2011","unstructured":"Gulrez G, Badyal DK, Deswal RS, Sharma A (2012) Bupropion as an augmenting agent in patients of depression with partial response. Basic Clin Pharmacol Toxicol 110(3):227\u2013230","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"11_CR22","doi-asserted-by":"crossref","unstructured":"Hobart M, Skuban A, Zhang P et al (2018a) A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2\u00a0mg\/d as adjunctive treatment of adults with major depressive disorder. J Clin Psychiatry 79(4):17m12058","DOI":"10.4088\/JCP.17m12058"},{"key":"11_CR23","doi-asserted-by":"crossref","unstructured":"Hobart M, Zhang P, Weiss C, Meehan SR, Eriksson H (2018b) Adjunctive brexpiprazole and functioning in major depressive disorder: a pooled analysis of six randomized studies using the Sheehan disability scale. Int J Neuropsychopharmacol 22(3):173\u2013179","DOI":"10.1093\/ijnp\/pyy095"},{"key":"11_CR24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/acps.12959","volume":"139","author":"A Kautzky","year":"2019","unstructured":"Kautzky A, Dold M, Bartova L, Spies M, Kranz GS, Souery D et al (2019) Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatr Scand 139:78\u201388","journal-title":"Acta Psychiatr Scand"},{"issue":"63","key":"11_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22630","volume":"22","author":"David Kessler","year":"2018","unstructured":"Kessler D, Burns A, Tallon D, Lewis G, MacNeill S, Round J et al (2018) Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. Health Technol Assess 22(63)","journal-title":"Health Technology Assessment"},{"issue":"1","key":"11_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40345-015-0032-2","volume":"3","author":"U Lewitzka","year":"2015","unstructured":"Lewitzka U, Severus E, Bauer R, Ritter P, M\u00fcller-Oerlinghausen B, Bauer M (2015) The suicide prevention effect of lithium: more than 20\u00a0years of evidence-a narrative review. Int J Bipolar Disord 3(1):32. \nhttps:\/\/doi.org\/10.1186\/s40345-015-0032-2","journal-title":"Int J Bipolar Disord"},{"key":"11_CR27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2147\/NDT.S127453","volume":"13","author":"S Luan","year":"2017","unstructured":"Luan S, Wan H, Wang S, Li H, Zhang B (2017) Efficacy and safety of olanzapine\/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat 13:609\u2013620","journal-title":"Neuropsychiatr Dis Treat"},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2147\/NDT.S156619","volume":"14","author":"S Luan","year":"2018","unstructured":"Luan S, Wan H, Zhang L, Zhao H (2018) Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat 14:467\u2013477","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"11_CR07","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2215-0366(15)00436-8","volume":"3","author":"R Hamish McAllister-Williams","year":"2016","unstructured":"McAllister-Williams RH, Anderson IM, Finkelmeyer A, Gallagher P, Grunze HC, Haddad PM, Hughes T, Lloyd AJ, Mamasoula C, McColl E, Pearce S (2016) Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. Lancet Psychiatry 3:117\u2013127","journal-title":"The Lancet Psychiatry"},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","volume":"156","author":"Roger S. McIntyre","year":"2014","unstructured":"McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS et al (2014) Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord 156:1\u20137","journal-title":"Journal of Affective Disorders"},{"key":"11_CR30","doi-asserted-by":"crossref","unstructured":"Mohamed S, Johnson GR, Chen P, et al (2017) Effect of antidepressant switching vs. augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. JAMA 318:132\u2013145","DOI":"10.1001\/jama.2017.8036"},{"key":"11_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/bdi.12701","volume":"20","author":"Roger Mulder","year":"2018","unstructured":"Mulder R, Hamilton A, Irwin L, Boyce P, Morris G, Porter RJ, Malhi GS (2018) Treating depression with adjunctive antipsychotics. Bipolar Disord (Suppl 2):17\u201324. \nhttps:\/\/doi.org\/10.1111\/bdi.12701","journal-title":"Bipolar Disorders"},{"issue":"9","key":"11_CR32","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","volume":"166","author":"J. Craig Nelson","year":"2009","unstructured":"Nelson JC, Papakostas GI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166(9):980\u2013991","journal-title":"American Journal of Psychiatry"},{"key":"11_CR33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jad.2014.05.053","volume":"156","author":"JC Nelson","year":"2014","unstructured":"Nelson JC, Baumann P, Delucchi K, Joffe R, Katona C (2014) A systematic review and meta-analysis of lithium augmentation in tricyclic and second generation antidepressants in major depression. J Affect Disord 156:269\u2013275","journal-title":"J Affect Disord"},{"issue":"3","key":"11_CR34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/1573400512666160816095900","volume":"12","author":"JC Nelson","year":"2016","unstructured":"Nelson JC, Zhang P, Skuban A et al (2016) Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment. Curr Psychiatry Rev 12(3):278\u2013290","journal-title":"Curr Psychiatry Rev"},{"issue":"3","key":"11_CR010","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1176\/appi.ajp.159.3.477","volume":"159","author":"Boris Nemets","year":"2002","unstructured":"Nemets B, Stahl Z, Belmaker RH (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 159:477\u2013479","journal-title":"American Journal of Psychiatry"},{"key":"11_CR35","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1176\/ajp.2006.163.9.1519","volume":"163","author":"AA Nierenberg","year":"2006","unstructured":"Nierenberg AA, Fava M, Trivedi MH et al (2006) A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163:1519\u20131530","journal-title":"Am J Psychiatry"},{"key":"11_CR36","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4088\/JCP.v68n0602","volume":"68","author":"GI Papakostas","year":"2007","unstructured":"Papakostas GI, Shelton RC, Smith J, Fava M (2007) Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 68:826\u2013831","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"11_CR37","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.biopsych.2007.08.010","volume":"63","author":"George I. Papakostas","year":"2008","unstructured":"Papakostas GI, Fava M, Thase ME (2008) Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 63(7):699\u2013704","journal-title":"Biological Psychiatry"},{"issue":"8","key":"11_CR04","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1176\/appi.ajp.2009.09081198","volume":"167","author":"George I. Papakostas","year":"2010","unstructured":"Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M (2010) S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 167:942\u2013948","journal-title":"American Journal of Psychiatry"},{"issue":"12","key":"11_CR05","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1176\/appi.ajp.2012.11071114","volume":"169","author":"George I. Papakostas","year":"2012","unstructured":"Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M (2012) L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 169:1267\u20131274","journal-title":"American Journal of Psychiatry"},{"issue":"10","key":"11_CR06","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/mp.2015.92","volume":"20","author":"G I Papakostas","year":"2015","unstructured":"Papakostas GI, Ionescu DF (2015) Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry 20:1142\u20131150","journal-title":"Molecular Psychiatry"},{"issue":"2","key":"11_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/2045125316629071","volume":"6","author":"Krisna Patel","year":"2016","unstructured":"Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK (2016) Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol 6(2):99\u2013144. \nhttps:\/\/doi.org\/10.1177\/2045125316629071\n\n. Epub 18 Feb 2016","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"9065","key":"11_CR02","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0140-6736(96)08007-5","volume":"349","author":"Victor P\u00e9rez","year":"1997","unstructured":"P\u00e9rez V, Gilaberte I, Faries D, Alvarez E, Artigas F (1997) Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349:1594\u20131597","journal-title":"The Lancet"},{"issue":"1","key":"11_CR39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12888-017-1412-1","volume":"17","author":"V P\u00e9rez","year":"2017","unstructured":"P\u00e9rez V, Salavert A, Espadaler J et al (2017) Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry 17(1):250","journal-title":"BMC Psychiatry"},{"key":"11_CR40","doi-asserted-by":"crossref","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME et al (2006a) STAR*D study team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354(12):1231\u20131242","DOI":"10.1056\/NEJMoa052963"},{"issue":"11","key":"11_CR41","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"A. John Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, et al (2006b) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. Am J Psychiatry 163:1905\u20131917","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"11_CR42","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archpsyc.65.8.870","volume":"65","author":"AJ Rush","year":"2008","unstructured":"Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M et al (2008) Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 65(8):870\u2013880","journal-title":"Arch Gen Psychiatry"},{"key":"11_CR43","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1176\/appi.ajp.2011.10111645","volume":"168","author":"AJ Rush","year":"2011","unstructured":"Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT et al (2011) Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 168:689\u2013701","journal-title":"Am J Psychiatry"},{"key":"11_CR44","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4088\/JCP.v67n0808","volume":"67","author":"GE Simon","year":"2006","unstructured":"Simon GE, Khandker RK, Ichikawa L, Operskalski BH (2006) Recovery from depression predicts lower health services costs. J Clin Psychiatry 67:1226\u20131231","journal-title":"J Clin Psychiatry"},{"key":"11_CR45","doi-asserted-by":"crossref","unstructured":"Smith KA, Cipriani A. Lithium and suicide in mood disorders: updated meta-review of the scientific literature.Bipolar Disord. 2017 Nov;19(7):575\u2013586","DOI":"10.1111\/bdi.12543"},{"key":"11_CR46","doi-asserted-by":"crossref","first-page":"e1001403","DOI":"10.1371\/journal.pmed.1001403","volume":"10","author":"GI Spielmans","year":"2013","unstructured":"Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013) Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 10:e1001403","journal-title":"PLoS Med"},{"issue":"7","key":"11_CR47","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.biopsych.2012.10.030","volume":"73","author":"KE Tansey","year":"2013","unstructured":"Tansey KE, Guipponi M, Hu X, Domenici E, Lewis G, Malafosse A et al (2013) Contribution of common genetic variants to antidepressant response. Biol Psychiatry 73(7):679\u2013682. \nhttps:\/\/doi.org\/10.1016\/j.biopsych.2012.10.030","journal-title":"Biol Psychiatry"},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/1573400512999160901094451","volume":"12","author":"ME Thase","year":"2016","unstructured":"Thase ME, Zhang P, Skuban A, Hobart M, Weiss C, Weiller E, Nelson JC (2016) Efficacy of adjunctive brexpiprazole in patients with major depressive disorder: a clinical overview. Curr Psychiatry Rev 12:291\u2013301","journal-title":"Curr Psychiatry Rev"},{"issue":"12","key":"11_CR49","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa052964","volume":"354","author":"Madhukar H. Trivedi","year":"2006","unstructured":"Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ (2006a) STAR*D study team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354(12):1243\u20131252","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"11_CR50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"Madhukar H. Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR et al (2006b) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163(1):28\u201340","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"11_CR51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4068\/cmj.2016.52.3.159","volume":"52","author":"SM Wang","year":"2016","unstructured":"Wang SM, Han C, Lee SJ et al (2016) Second generation antipsychotics in the treatment of major depressive disorder: an update. Chonnam Med J. 52(3):159\u2013172","journal-title":"Chonnam Med J."},{"key":"11_CR52","unstructured":"WHO (2018) Depression fact sheet. \nhttps:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/depression\n\n. Accessed 17 Mar 2019"},{"key":"11_CR53","doi-asserted-by":"crossref","unstructured":"Zisook S, Johnson GR, Tal I, Hicks P, Chen P, Davis L et al (2019) General predictors and moderators of depression remission: a VAST-D report. Am J Psychiatry Published online 4 May 2019","DOI":"10.1176\/appi.ajp.2018.18091079"}],"container-title":["Advances in Experimental Medicine and Biology","Depressive Disorders: Mechanisms, Measurement and Management"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-32-9271-0_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T14:08:18Z","timestamp":1583590098000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-981-32-9271-0_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9789813292703","9789813292710"],"references-count":63,"URL":"https:\/\/doi.org\/10.1007\/978-981-32-9271-0_11","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"30 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}